- Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Interventions
- IRX-2, Cyclophosphamide, Indomethacin, Zinc-containing multivitamin, Omeprazole
- Biological · Drug · Dietary Supplement
- Lead sponsor
- Brooklyn ImmunoTherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 3,857
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Placebo Q2W, Tralokinumab 300 mg, Q2W, Placebo, Q2/4W, Tralokinumab 300 mg, Q2/4W
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 11
- States / cities
- Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Herpes Zoster, HIV Infections
- Interventions
- ZOSTAVAX, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- Metreleptin
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more
- Conditions
- CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Subcutaneous Blinatumomab
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
- Conditions
- Achondroplasia
- Interventions
- BMN 111, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 11
- States / cities
- Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
- Conditions
- Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
- Interventions
- Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hepatitis C
- Interventions
- SOF, RBV, Peg-IFN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 23
- States / cities
- Riverside, California • San Diego, California • San Francisco, California + 19 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more
- Conditions
- Malignant Carcinoid Syndrome
- Interventions
- lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Rheumatoid Arthritis
- Interventions
- Teriparatide, calcium citrate, Vitamin D, TNF antagonist
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts
- Conditions
- Achondroplasia
- Interventions
- Navepegritide, Placebo for Navepegritide
- Drug
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab
- Biological
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Icatibant (30 mg)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Scar, Cesarean Section; Dehiscence
- Interventions
- Scar Deactivation Surface Release Technique protocol, Scar Infiltration with 0.25-1% Lidocaine, Physical therapy
- Other
- Lead sponsor
- Jennifer Loomis
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Scott Air Force Base, Illinois
- Conditions
- Osteoarthritis, Knee
- Interventions
- Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
- Drug
- Lead sponsor
- ROC Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Obesity, Genetic Obesity
- Interventions
- Setmelanotide, Placebo
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Cardiac Sarcoidosis
- Interventions
- Rilonacept
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Rochester, Minnesota
- Conditions
- High Cardiovascular Risk, Hypertension
- Interventions
- Zilebesiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 139
- States / cities
- Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
- Conditions
- Hereditary Angioedema
- Interventions
- STAR-0215
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 9 more
- Conditions
- Impaired Renal Function
- Interventions
- Aldafermin (NGM282)
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida